April 1, 2015

SAN FRANCISCO — Three-fourths of men with anogenital warts caused by human papillomavirus (HPV) had clinical remission and the rest had partial responses to a frog-derived enzyme, investigators reported here.

Clinical remission occurred in 18 of 24 evaluable patients in response to ranpirnase, an endoribonuclease derived from the eggs of Rana pipiens, or Northern Leopard frog. The patients received 1 mg/mL BID of a topical formulation of ranpirnase, and remissions occurred, on average, within 33 days of starting treatment, Luis Squiquera, MD, of Tamir Biotechnology, reported at the American Academy of Dermatology meeting.

Read the full article here.

Back to top